This study investigated the ability of
hepatitis B core-related
antigen (HBcrAg) to predict hepatitis B virus (HBV) relapse in
HBeAg-negative patients after cessation of
entecavir therapy. A total of 301
HBeAg-negative patients without
cirrhosis who had stopped
entecavir therapy for at least 12 months were recruited. All patients fulfilled the stopping criteria proposed by the APASL 2012 guidelines. The five-year cumulative rates of virological relapse, clinical relapse and
HBsAg loss were 71.6%, 57.3% and 18.7%, respectively. Serum
HBsAg at end of treatment (EOT) was an independent predictor of virological relapse, clinical relapse and
HBsAg loss; an EOT
HBsAg of 150 IU/ml was the optimal cut-off value. The 5-year virological relapse rates for patients with <150 and ≥150 IU/ml
HBsAg at EOT were 43.3% and 82.2% (p < 0.001), clinical relapse rates were 32.3% and 66.3% (p < 0.001), and
HBsAg loss rates were 46.1% and 5.2% (p < 0.001), respectively. A baseline HBcrAg of 4 IU/ml was the optimal cut-off value for predicting HBV relapse. Among patients with an EOT
HBsAg <150 IU/ml, the five-year virological relapse rates for patients with baseline HBcrAg levels ≤4 and >4 log U/ml were 27.9% and 59.1% (p = 0.006) and the clinical relapse rates were 18% and 48.1% (p = 0.014), respectively. EOT HBcrAg was not a significant predictor of virological or clinical relapse after cessation of
entecavir. In conclusion, the combination of an EOT
HBsAg of 150 IU/ml and baseline HBcrAg of 4 log U/ml can effectively predict the risk of HBV relapse after stopping
entecavir therapy.